We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
Read MoreHide Full Article
Protagonist Therapeutics, Inc. (PTGX - Free Report) announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated icotrokinra (JNJ-2113), an investigational targeted oral peptide that selectively blocks the IL-23 receptor, for treating adults with moderately to severely active ulcerative colitis (UC), a chronic disease of the large intestine.
The ANTHEM-UC study, conducted by Protagonist's partner, Johnson & Johnson (JNJ - Free Report) , met its primary endpoint of clinical response in all icotrokinra dose groups.
Treatment with icotrokinra also demonstrated clinically meaningful differences in key secondary endpoints of clinical remission, symptomatic remission and endoscopic improvement at week 12 versus placebo in the ANTHEM-UC study.
Shares of PTGX were up 45.9% on March 10 following the announcement of the news.
In the past year, shares of Protagonist have rallied 87.4% against the industry’s decline of 8.5%.
Image Source: Zacks Investment Research
PTGX & JNJ's ANTHEM-UC Study Data in Details
The randomized, placebo-controlled phase IIb ANTHEM-UC study evaluated the safety and efficacy of three once-daily oral dosages of icotrokinra in patients with moderately to severely active UC who had an inadequate response or are intolerant to conventional therapy.
All three doses of icotrokinra met the primary endpoint of clinical response at week 12.
Patients treated with the highest dose of icotrokinra achieved a response rate of 63.5% as compared to 11.1% of patients receiving placebo at week 12. Also, 30.2% of patients treated with the highest dose of icotrokinra showed clinical remission at week 12 compared with 11.1% of patients who received placebo.
Treatment with icotrokinra was generally safe and well tolerated.
More on PTGX & JNJ's Partnership for Icotrokinra
Icotrokinra was jointly discovered by Protagonist and Johnson & Johnson. The candidate is now being developed under the companies' license and collaboration agreement.
Protagonist primarily developed icotrokinra through phase I studies. JNJ holds exclusive worldwide rights to develop icotrokinra in phase II studies and beyond.
Icotrokinra is also being investigated in the pivotal phase III ICONIC clinical program for treating moderate-to-severe plaque psoriasis and active psoriatic arthritis.
Last week, Protagonist announced new data from the phase III ICONIC-LEAD study and phase III ICONIC-ADVANCE 1&2 studies on icotrokinra for treating moderate-to-severe plaque psoriasis (PsO).
Data from the phase III ICONIC-LEAD study showed that almost half of patients with moderate-to-severe PsO who were treated with icotrokinra achieved completely clear skin at week 24.
Data from the phase III ICONIC-ADVANCE 1&2 studies, which evaluated icotrokinra versus Bristol Myers’ (BMY - Free Report) psoriasis drug, Sotyktu (deucravacitinib), met the co-primary endpoints with icotrokinra proving its superiority to BMY's Sotyktu.
As icotrokinra outperformed BMY’s Sotyktu in the ICONIC-ADVANCE 1&2 studies, J&J is now planning to initiate the phase III ICONIC-ASCENDe head-to-head study to evaluate the potential and superiority of oral icotrokinra, compared to its blockbuster injectable biologic, Stelara (ustekinumab) for treating moderate-to-severe plaque PsO.
PTGX's Zacks Rank & A Stock to Consider
Protagonist currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for BioMarin’s earnings per share have increased from $4.01 to $4.25 for 2025. In the past year, shares of BMRN have declined 15.4%.
BMRN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 32.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
Protagonist Therapeutics, Inc. (PTGX - Free Report) announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated icotrokinra (JNJ-2113), an investigational targeted oral peptide that selectively blocks the IL-23 receptor, for treating adults with moderately to severely active ulcerative colitis (UC), a chronic disease of the large intestine.
The ANTHEM-UC study, conducted by Protagonist's partner, Johnson & Johnson (JNJ - Free Report) , met its primary endpoint of clinical response in all icotrokinra dose groups.
Treatment with icotrokinra also demonstrated clinically meaningful differences in key secondary endpoints of clinical remission, symptomatic remission and endoscopic improvement at week 12 versus placebo in the ANTHEM-UC study.
Shares of PTGX were up 45.9% on March 10 following the announcement of the news.
In the past year, shares of Protagonist have rallied 87.4% against the industry’s decline of 8.5%.
Image Source: Zacks Investment Research
PTGX & JNJ's ANTHEM-UC Study Data in Details
The randomized, placebo-controlled phase IIb ANTHEM-UC study evaluated the safety and efficacy of three once-daily oral dosages of icotrokinra in patients with moderately to severely active UC who had an inadequate response or are intolerant to conventional therapy.
All three doses of icotrokinra met the primary endpoint of clinical response at week 12.
Patients treated with the highest dose of icotrokinra achieved a response rate of 63.5% as compared to 11.1% of patients receiving placebo at week 12. Also, 30.2% of patients treated with the highest dose of icotrokinra showed clinical remission at week 12 compared with 11.1% of patients who received placebo.
Treatment with icotrokinra was generally safe and well tolerated.
More on PTGX & JNJ's Partnership for Icotrokinra
Icotrokinra was jointly discovered by Protagonist and Johnson & Johnson. The candidate is now being developed under the companies' license and collaboration agreement.
Protagonist primarily developed icotrokinra through phase I studies. JNJ holds exclusive worldwide rights to develop icotrokinra in phase II studies and beyond.
Icotrokinra is also being investigated in the pivotal phase III ICONIC clinical program for treating moderate-to-severe plaque psoriasis and active psoriatic arthritis.
Last week, Protagonist announced new data from the phase III ICONIC-LEAD study and phase III ICONIC-ADVANCE 1&2 studies on icotrokinra for treating moderate-to-severe plaque psoriasis (PsO).
Data from the phase III ICONIC-LEAD study showed that almost half of patients with moderate-to-severe PsO who were treated with icotrokinra achieved completely clear skin at week 24.
Data from the phase III ICONIC-ADVANCE 1&2 studies, which evaluated icotrokinra versus Bristol Myers’ (BMY - Free Report) psoriasis drug, Sotyktu (deucravacitinib), met the co-primary endpoints with icotrokinra proving its superiority to BMY's Sotyktu.
As icotrokinra outperformed BMY’s Sotyktu in the ICONIC-ADVANCE 1&2 studies, J&J is now planning to initiate the phase III ICONIC-ASCENDe head-to-head study to evaluate the potential and superiority of oral icotrokinra, compared to its blockbuster injectable biologic, Stelara (ustekinumab) for treating moderate-to-severe plaque PsO.
PTGX's Zacks Rank & A Stock to Consider
Protagonist currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is BioMarin Pharmaceutical Inc. (BMRN - Free Report) , carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for BioMarin’s earnings per share have increased from $4.01 to $4.25 for 2025. In the past year, shares of BMRN have declined 15.4%.
BMRN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 32.36%.